Osteoporosis Medication After a Fracture

A broken wrist, hip, shoulder, pelvis, or vertebra after a simple fall may be more than an isolated injury. It can be a warning that the skeleton is vulnerable to another fracture.

Once the immediate fracture is treated, many patients face a new question: Which osteoporosis medication is right for me? The names can be confusing. Some medicines slow bone breakdown. Others build new bone. Some are tablets, some are injections, and some are infusions. Several also require a follow-up medicine when the first course ends.

There is no single best drug for everyone. The right plan depends on fracture history, bone density, kidney function, calcium and vitamin D status, heart and stroke history, dental health, other medications, and how reliably a treatment schedule can be followed.

Key takeaway: After a fragility fracture, treatment should be selected according to the risk of another fracture, not just one DXA number. Bisphosphonates such as alendronate or zoledronic acid are common first choices for many people at high risk. Denosumab can be an effective alternative but should not be delayed or stopped without a transition plan. Bone-building treatment such as romosozumab may be considered first for selected patients at very high risk, followed by an antiresorptive medicine.

Why a fracture changes the medication conversation

A fragility fracture generally means a bone broke after low-energy trauma, such as a fall from standing height. Hip and vertebral fractures are especially important signals. A wrist, shoulder, or pelvic fracture in an adult over 50 can also prompt evaluation for osteoporosis and other causes of weak bone.

The Bone Health and Osteoporosis Foundation clinician guide emphasizes that a previous fracture strongly affects future fracture risk. It also notes that osteoporosis remains a long-term diagnosis even if treatment later improves a bone-density score.

This is why the decision is not simply “Is my T-score below -2.5?” A clinician may consider:

The type and timing of prior fractures
Whether more than one fracture has occurred
DXA measurements at the hip and spine
Vertebral fractures that may be visible on imaging even without a memorable injury
Age, fall risk, weight, smoking, alcohol use, and family history
Long-term steroid treatment or other medicines that weaken bone
Kidney, thyroid, parathyroid, intestinal, blood, or inflammatory disorders
Whether fracture risk is high or very high

If the original injury may have been a low-trauma break, our guide to fragility fractures and osteoporosis explains why evaluation should continue after the bone itself has been stabilized.

What should be checked before starting treatment?

Medication selection should follow a focused evaluation. The goal is to confirm the diagnosis, look for reversible contributors, and identify safety issues that change the choice of drug.

The workup may include:

Review of the fracture and prior imaging
DXA bone-density testing, usually at the hip and lumbar spine
Height measurement and consideration of vertebral imaging
Blood calcium and kidney function
Vitamin D level when appropriate
Additional laboratory testing based on history, such as thyroid, parathyroid, blood-count, liver, or protein studies
Review of calcium intake, nutrition, exercise, balance, and fall risk
Medication and dental history

A clinician may also use FRAX or another risk assessment tool. These tools estimate fracture probability, but they do not capture every important feature. A recent hip or vertebral fracture, multiple fractures, very low bone density, or a fall-prone patient may warrant more intensive treatment than a calculator alone suggests.

Two broad treatment strategies

Osteoporosis medicines are often grouped by what they do to bone remodeling.

Antiresorptive medicines slow bone breakdown

These include bisphosphonates and denosumab. They reduce the activity of cells that remove bone. This allows bone density and strength to stabilize or improve over time.

Common examples include:

Alendronate, an oral bisphosphonate usually taken weekly
Risedronate, another oral bisphosphonate
Zoledronic acid (Reclast), an intravenous bisphosphonate generally given once yearly for osteoporosis
Denosumab (Prolia), an injection given every six months

Bone-building medicines stimulate bone formation

These are also called anabolic or dual-action therapies. They are often considered when fracture risk is very high.

Examples include:

Romosozumab (Evenity), monthly treatment for 12 months that both increases bone formation and reduces bone resorption
Teriparatide and abaloparatide, daily self-injections used for a limited treatment course

Bone-building treatment is not usually the end of the plan. An antiresorptive medicine generally follows to preserve the gains.

When is an oral bisphosphonate a reasonable first choice?

The Endocrine Society guideline recommends bisphosphonates as initial treatment for many postmenopausal women at high fracture risk. Oral alendronate is commonly used because it has extensive fracture-prevention evidence and is available as a generic medication.

Oral treatment may fit a patient who:

Is at high, but not necessarily very high, fracture risk
Can follow the dosing instructions consistently
Can remain upright after taking the tablet
Does not have a major swallowing or esophageal problem
Has kidney function suitable for that medicine
Prefers a tablet to an injection or infusion

The instructions matter because oral bisphosphonates are absorbed poorly and can irritate the esophagus. The exact directions vary by product, but alendronate is generally taken with plain water on an empty stomach, followed by a waiting period before food, drink, or other medicines. Patients must remain upright during that period.

Some people later qualify for a monitored bisphosphonate holiday because these medicines remain in bone after dosing stops. A holiday is not the same as abandoning treatment. It is a planned pause for selected lower-risk patients after several years, with periodic reassessment. Someone who remains at high risk may need continued or different therapy.

When does Reclast make sense?

Zoledronic acid, sold as Reclast for osteoporosis, is given through an IV. It can be useful when a patient cannot tolerate oral bisphosphonates, has difficulty following weekly tablet instructions, has absorption concerns, or simply prefers infrequent dosing.

Important considerations include:

Kidney function must be reviewed before treatment.
Calcium and vitamin D problems should be corrected.
Some people develop a short-lived flu-like reaction after the first infusion, with fever, muscle aches, headache, or fatigue.
Hydration and the timing of certain other medicines may matter.
The number and spacing of doses should reflect fracture risk and response.

Reclast is not appropriate for every patient with kidney disease. A clinician should calculate kidney function and review the current prescribing information rather than relying on a casual impression that the kidneys are “fine.”

When does Prolia make sense?

Denosumab, sold as Prolia, is an antiresorptive injection given every six months. It can reduce vertebral, hip, and other fractures in appropriate patients. It may be considered when bisphosphonates are not a good fit or as an alternative initial treatment for a patient at high risk.

Prolia differs from a bisphosphonate in one crucial way: its effect wears off relatively quickly if a dose is missed or treatment is stopped. Bone turnover can rebound, bone density can fall rapidly, and vertebral fractures can occur. The Endocrine Society specifically advises against delaying or stopping denosumab without another antiresorptive treatment to prevent rebound bone loss and fracture.

That means Prolia requires a long-term scheduling and transition plan from the start. Patients should know:

Six-month injections need to remain on schedule.
Travel, insurance changes, dental work, or a change of clinician should be planned around the next dose rather than allowed to create an unreviewed gap.
Stopping generally requires another medicine, often a bisphosphonate, at an appropriate time.
Low calcium must be corrected before treatment.

Kidney function requires special attention. In January 2024, the FDA added a boxed warning because Prolia can cause severe hypocalcemia in patients with advanced chronic kidney disease, especially those on dialysis or with chronic kidney disease-mineral and bone disorder. Patients in this group need expert selection, calcium management, and close monitoring.

When might Evenity be considered first?

Romosozumab, sold as Evenity, is a 12-month bone-building treatment for selected postmenopausal women at high risk for fracture. The Endocrine Society guideline supports it for women at very high risk, such as those with severe osteoporosis plus fractures or multiple vertebral fractures.

This “build first” approach can be valuable when the immediate risk of another fracture is especially high. Evenity is given monthly by a healthcare professional. After 12 doses, treatment is followed by an antiresorptive medicine such as a bisphosphonate or denosumab so that the bone-density gains are not lost.

Evenity also has an important cardiovascular warning. The FDA prescribing information states that it should not be started in a patient who has had a heart attack or stroke within the preceding year. Other cardiovascular risk factors also need to be weighed carefully. If a heart attack or stroke occurs during treatment, the medicine should be discontinued and emergency care obtained.

The choice is therefore not based on bone density alone. Fracture urgency has to be balanced against cardiovascular history, calcium status, kidney function, and the ability to complete the planned follow-up therapy.

What about teriparatide and abaloparatide?

Teriparatide and abaloparatide are bone-building medicines given as daily self-injections. They may be considered for very high-risk patients, including some people with severe or multiple vertebral fractures.

These treatments have time limits and specific contraindications. They may not be appropriate for someone with certain bone disorders, unexplained laboratory abnormalities, skeletal radiation exposure, or particular cancers. A clinician should review the full history rather than treating them as interchangeable with every other osteoporosis medicine.

As with Evenity, an antiresorptive medicine is generally used afterward to maintain the improvement in bone density.

Is one medication “stronger” than another?

That question is understandable, but it can be misleading. A medicine is useful only if it matches the patient’s risk and can be taken safely and consistently.

For example:

A weekly pill may be an excellent option for one patient and impractical for another with severe reflux or difficulty swallowing.
A yearly infusion may simplify adherence but be unsuitable with impaired kidney function.
A six-month injection can be convenient, but it creates risk if follow-up is unreliable or advanced kidney disease is present.
A bone-building medicine may be preferred after multiple fractures, but it still needs a safety review and a follow-on treatment.

The sequence can matter as much as the individual drug. In a very high-risk patient, building bone first and then maintaining it may offer advantages over starting with a long course of antiresorptive treatment. For another patient, a bisphosphonate may provide the best balance of evidence, safety, convenience, and cost.

What risks worry patients most?

Osteonecrosis of the jaw

Osteonecrosis of the jaw is a rare complication with osteoporosis-dose antiresorptive treatment. Risk is higher with much larger doses used for some cancers. Active dental infection, invasive dental procedures, smoking, diabetes, and prolonged exposure may increase risk.

This possibility should be discussed, but fear of a rare complication should be balanced against the much more immediate danger of a hip or vertebral fracture in a high-risk patient. Good oral hygiene, routine dental care, and communication between the prescribing clinician and dentist are sensible. Patients should not stop Prolia or another medicine on their own for dental work.

Atypical femur fracture

Long-term antiresorptive therapy is associated with a rare type of thigh-bone fracture. New, persistent thigh or groin pain should be reported because imaging may identify a stress reaction before a complete fracture. Risk assessment over time helps determine whether continued therapy, a holiday, or a change in treatment is appropriate.

Low calcium

Several osteoporosis medicines can lower blood calcium. Vitamin D deficiency, malabsorption, low intake, parathyroid disorders, and kidney disease can increase risk. Correcting low calcium and reviewing vitamin D status before treatment are important safety steps.

Heart and stroke risk

This concern is particularly relevant to Evenity. It requires an individualized cardiovascular review and should never be reduced to a simple yes-or-no checklist without context.

Will osteoporosis medication interfere with fracture healing?

Patients sometimes fear that treatment will prevent a fracture from healing. In most situations, appropriate osteoporosis treatment does not need to be postponed for months while waiting for complete radiographic union. The timing can depend on the fracture, operation, calcium status, and chosen drug, so the orthopedic and bone-health plans should be coordinated.

An anabolic medicine may be selected for overall fracture risk in some patients, but it should not be presented as a guaranteed way to heal a specific fracture. A delayed union or nonunion still requires evaluation of alignment, stability, blood supply, infection, nutrition, and other causes.

Medication is only one part of fracture prevention

Even a very effective medicine cannot prevent every fracture. A complete plan also addresses:

Adequate protein and overall nutrition
Calcium primarily from food, with supplements when needed
Vitamin D based on individual needs and laboratory findings
Progressive resistance and weight-bearing activity when safe
Balance training and fall-risk reduction
Vision, footwear, home hazards, and sedating medicines
Smoking cessation and moderation of alcohol
Treatment of contributing medical conditions

Physical therapy can be especially helpful after a fracture, during deconditioning, or when balance and confidence have declined. Exercise recommendations should match the location of prior fractures and current fall risk.

How is response monitored?

Monitoring is not only a repeat DXA scan. Follow-up may include:

Confirmation that doses were received on time
Review of falls, new fractures, height loss, and new back pain
Calcium, vitamin D, kidney, or other laboratory testing when indicated
Repeat DXA, often after one to three years depending on risk and treatment
Review of side effects and barriers to adherence
A written plan for when a limited course ends or a medicine must be changed

A fracture during therapy does not automatically mean the medicine failed. Clinicians first check adherence, treatment duration, new medical causes, and whether the fracture occurred before the drug had enough time to work. Multiple fractures or substantial bone loss despite treatment may justify a change in strategy.

Questions to bring to a bone-health visit

Consider asking:

Is my fracture likely related to osteoporosis?
Am I at high or very high risk for another fracture?
Do I need a DXA scan, vertebral imaging, or additional blood tests?
Why are you recommending this medicine over the alternatives?
How do my kidneys, calcium level, dental health, and cardiovascular history affect the choice?
What happens if a dose is late?
How long will I use this medicine?
What treatment comes next when this course ends?
When should bone density and laboratory tests be repeated?
Which symptoms require a prompt call or emergency care?

When to seek urgent care

Osteoporosis itself usually does not cause an emergency until a fracture or serious treatment complication occurs. Seek urgent evaluation after a fall or sudden pain if you cannot bear weight, have a visibly deformed limb, develop new weakness or numbness, lose bladder or bowel control, or have severe back pain with neurologic symptoms.

Call emergency services for possible heart attack or stroke symptoms, including chest pressure, sudden shortness of breath, facial droop, one-sided weakness, or sudden difficulty speaking. Severe confusion, fainting, seizure, or uncontrolled muscle spasms after an osteoporosis injection can be a sign of dangerously low calcium and also needs urgent care.

The practical next step

If you have had a low-trauma fracture, very low bone density, or uncertainty about Prolia, Reclast, Evenity, or another treatment, the next step is a risk-based plan rather than choosing a drug from a list. Pacific Bone & Joint’s bone health and osteoporosis service evaluates fracture history, DXA findings, laboratory results, medical risks, and treatment sequencing.

Request a bone-health evaluation to review which treatment approach fits your fracture risk and what the follow-up plan should be before the first dose is given.

Sources and further reading

This article provides general education and does not replace individualized medical advice. Medication indications, contraindications, coverage, and monitoring vary by patient and can change over time.

This article is educational and is not a substitute for medical advice. Individual results vary.

Osteoporosis Medication After a Fracture: How Prolia, Reclast, and Evenity Differ